Chief Executive Officer, Slate Medicines
Appears in 1 story
Set to lead the combined public company
Fulcrum Therapeutics spent two years watching its two lead drugs fail. On August 17, 2026, the shell that remained agreed to merge with Slate Medicines, a privately held migraine startup, in an all-stock deal backed by a $245 million private placement.
Updated 6 minutes ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
